Sunovion Answers Plus | LONHALA® MAGNAIR® (glycopyrrolate)

Sunovion Answers Plus for LONHALA® MAGNAIR®

Sunovion Answers (SA) Plus for LONHALA MAGNAIR is the new intake and distribution model for LONHALA MAGNAIR prescriptions. This new model will provide a more uniform and high-quality experience for you and your patients.

Here's how to get started

Use the form below to prescribe LONHALA MAGNAIR to your patients, and then offer them the accompanying patient guide to provide details on what comes next after enrollment.

Download the form and print before faxing

Download the form and print before faxing

Enrollment form for newly prescribed patients

Download Now  

 

Enrollment form for currently prescribed patients

Download Now  

 

For enrollment of new patients into SA plus for LONHALA MAGNAIR through Electronic Health Record (EHR), choose TC Script, LLC in your EHR electronic prescription system.  If TC Scripts, LLC is not an option in your EHR, it can be added using the following codes:

  • NCPDP # = 0362501
  • NPI # = 1104391770

Fax the enrollment form to 1-833-664-7126


Download and offer this letter to your existing patients, which details the new program

Letter to Patients

Download Now  

 

 

Prescriptions written in long-term care (LTC) facilities will not use SA Plus for LONHALA MAGNAIR. Learn how to prescribe in LTC facilities here.


What your patients can expect for their prescription

SA Plus for LONHALA MAGNAIR is a prescription processing program that:

 
 

Gives patients a call within 24 hours of enrollment and performs a benefits investigation

Assists with the prior authorization process (if necessary)

 
 

Determines and confirms co-pay savings for eligible patients

Triages the prescription to a participating pharmacy of the patient’s choice

 
 

SA Plus for LONHALA MAGNAIR is a prescription processing program that:

 
 

Gives patients a call within 24 hours of enrollment and performs a benefits investigation

 
 

Assists with the prior authorization process (if necessary)

 
 

Determines and confirms co-pay savings

 
 

Triages the prescription to a participating pharmacy of the patient’s choice

 
 

Once approved, patients may either pick up their prescription or receive it by mail if the pharmacy provides this service

 
 

SA Plus for LONHALA MAGNAIR also provides:

 
 

Ongoing device training

Educational resources

Refill reminder calls

 
 

SA Plus for LONHALA MAGNAIR also provides:

 
 

Ongoing device training

 
 

Educational resources

 
 

Refill reminder calls

 
 

Sunovion Answers Plus for LONHALA MAGNAIR will reach out if any additional information is needed



Sunovion Answers Plus for LONHALA MAGNAIR will reach out if any additional information is needed


Prescription-to-fill process

Want more information?

Watch a video detailing the step-by-step process from start to finish.


 


Need support?

Specialists are available between 8 am and 8 pm ET, Monday through Friday.

1-844-276-8262

Important Safety Information & Indication

Important Safety Information
 

LONHALA MAGNAIR is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

LONHALA MAGNAIR should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, LONHALA MAGNAIR can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with LONHALA MAGNAIR, it should be treated immediately with an inhaled, short-acting bronchodilator; LONHALA MAGNAIR should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with LONHALA MAGNAIR. If signs occur, discontinue LONHALA MAGNAIR immediately and institute alternative therapy.

LONHALA MAGNAIR should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥2% of patients taking LONHALA MAGNAIR, and occurring more frequently than in patients taking placebo, were dyspnea (4.9% vs 3.0%) and urinary tract infection (2.1% vs 1.4%).

LONHALA solution is for oral inhalation only and should not be injected or swallowed. LONHALA vials should only be administered with MAGNAIR.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for LONHALA MAGNAIR at www.sunovionprofile.com/lonhala-magnair.

Indication
 

LONHALA® MAGNAIR® (glycopyrrolate) is an anticholinergic indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.